Publication Date
10-11-2022
Journal
Journal of Clinical Medicine
DOI
10.3390/jcm11205977
PMID
36294298
PMCID
PMC9604376
PubMedCentral® Posted Date
10-11-2022
PubMedCentral® Full Text Version
Post-print
Published Open-Access
yes
Keywords
immune checkpoint inhibitors, immunotherapy, immune-related hepatitis, acute kidney injury, myositis, myocarditis
Abstract
There are differences in recommendations for the management of immune-related adverse events (irAEs) associated with immune checkpoint inhibitors (ICIs). To assess the real-world management of irAEs, three surveys regarding ICI-induced hepatitis (IIH), renal irAEs, and myositis were developed and sent to experts in each area. Fifty-six surveys were completed (17 IIH, 20 renal irAEs, and 19 myositis). All experts agreed on performing imaging in every suspected case of severe IIH. Sixty-five percent agreed on performing a liver biopsy in patients not responding to corticosteroids. The most common indication for corticosteroid use (59%) was for severe IIH not improving after discontinuation of ICIs. Additionally, 60% of the experts agreed on performing a biopsy for stage 2/3 acute kidney injury (AKI), and 70% recommended imaging for any stage of AKI. Thirty-five percent favored corticosteroids in AKI patients with creatinine levels 2-3-fold above baseline. For myositis, 58% would recommend a muscle biopsy in a patient with weakness and creatine kinase levels of 5000 U/L; 47% would also opt for an endomyocardial biopsy when the troponin levels are increased. Fifty-eight percent recommended oral corticosteroids for myositis, and 37% recommended additional therapy, mainly immunoglobulins. These results show substantial differences in expert practice patterns for the management of severe liver, kidney, and muscular irAEs.
- Citations
- Citation Indexes: 6
- Usage
- Downloads: 12
- Captures
- Readers: 11
- Mentions
- Blog Mentions: 1
- News Mentions: 1
Included in
Allergy and Immunology Commons, Immune System Diseases Commons, Medical Immunology Commons
